- ISIN
- US9183851057
- CUSIP
- 918385105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 30, 2015
Highlights
- Market Cap
- $496.40M
- Enterprise Value
- $398.31M
- EPS (TTM)
- $0.24
- PE Ratio
- 141.96
- Total Revenue (TTM)
- $36.84M
- Gross Profit (TTM)
- -$2.00K
- EBITDA (TTM)
- -$3.04M
- Year Range
- $14.00 - $44.00
- Target Price
- $51.33
- ROA (TTM)
- 2.28%
- ROE (TTM)
- 2.50%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VTVT Performance Chart
vTv Therapeutics Inc. (VTVT) is down 15.2% since the beginning of the year. At $34 per share, VTVT is trading 22.9% below its 52-week high of $44. Investors who bought $1,000 worth of VTVT shares 5 years ago would now be looking at an investment worth $338.
Loading charts...
Returns By Period
vTv Therapeutics Inc. (VTVT) has returned -15.18% so far this year and 118.19% over the past 12 months. Over the last ten years, VTVT has returned -17.69% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
vTv Therapeutics Inc.
- 1D
- -3.20%
- 1M
- -1.41%
- YTD
- -15.18%
- 6M
- -7.45%
- 1Y
- 118.19%
- 3Y*
- 3.11%
- 5Y*
- -19.51%
- 10Y*
- -17.69%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
VTVT Monthly Returns History
Based on dividend-adjusted daily data since Jul 30, 2015, VTVT's average daily return is +0.13%, while the average monthly return is +1.12%. At this rate, an investment would double in approximately 5.2 years.
Historically, 39% of months were positive and 61% were negative. The best month was Oct 2018 with a return of +240.3%, while the worst month was Apr 2018 at -56.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 10 months.
On a daily basis, VTVT closed higher 44% of trading days. The best single day was Oct 2, 2018 with a return of +157.7%, while the worst single day was Apr 10, 2018 at -78.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.45% | 7.77% | 3.93% | -18.71% | 3.44% | 1.71% | -15.18% | ||||||
| 2025 | 17.24% | 21.43% | -11.90% | 15.18% | -20.35% | -5.60% | -0.33% | 8.63% | 43.78% | -6.85% | 22.76% | 49.78% | 189.60% |
| 2024 | -26.87% | 108.68% | 34.07% | 18.57% | -16.38% | -24.30% | -17.89% | 8.34% | -13.65% | 1.11% | 16.95% | -13.91% | 20.08% |
| 2023 | 43.30% | -14.72% | -0.27% | -4.68% | 2.60% | -6.35% | -8.62% | -24.56% | -6.27% | -12.76% | -14.33% | -19.52% | -56.62% |
| 2022 | -27.99% | 14.25% | -11.79% | -4.42% | -20.14% | 36.07% | 20.00% | 17.78% | -8.49% | -10.93% | -4.58% | -19.60% | -33.39% |
| 2021 | 9.68% | 30.39% | 6.02% | -9.22% | -3.91% | -7.32% | -15.79% | -2.60% | -18.18% | -6.54% | -13.29% | -19.76% | -46.51% |
Benchmark Metrics
vTv Therapeutics Inc. has an annualized alpha of 24.96%, beta of 0.80, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since July 30, 2015.
- This stock participated in 1.63% of S&P 500 Index downside but only -63.32% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 24.96%
- Beta
- 0.80
- R²
- 0.02
- Upside Capture
- -63.32%
- Downside Capture
- 1.63%
Return for Risk
Risk / Return Rank
VTVT ranks 83 for risk / return — in the top 83% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for vTv Therapeutics Inc. (VTVT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VTVT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.46 | ||
| Sortino ratioReturn per unit of downside risk | -0.54 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.37 | -0.09 |
| Calmar ratioReturn relative to maximum drawdown | 3.71 | 2.78 | +0.92 |
| Martin ratioReturn relative to average drawdown | 8.36 | 12.44 | -4.08 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the vTv Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the vTv Therapeutics Inc. was 98.59%, occurring on Jan 25, 2024. The portfolio has not yet recovered.
The current vTv Therapeutics Inc. drawdown is 93.94%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -98.59%Jan 2024 | 8y 6mo | — | 10y 11moJul 2015 - now |
Drawdown Indicators
| VTVT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.59% | -56.78% | -41.81% |
Max Drawdown (1Y)Largest decline over 1 year | -32.06% | -9.10% | -22.96% |
Max Drawdown (3Y)Largest decline over 3 years | -74.52% | -18.90% | -55.62% |
Max Drawdown (5Y)Largest decline over 5 years | -91.72% | -25.43% | -66.29% |
Max Drawdown (10Y)Largest decline over 10 years | -97.48% | -33.92% | -63.56% |
Current DrawdownCurrent decline from peak | -93.94% | -1.80% | -92.14% |
Average DrawdownAverage peak-to-trough decline | -82.79% | -10.71% | -72.08% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.19% | 2.03% | +12.16% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of vTv Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how vTv Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for VTVT, comparing it with other companies in the Biotechnology industry. Currently, VTVT has a P/E ratio of 142.0. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VTVT relative to other companies in the Biotechnology industry. Currently, VTVT has a P/S ratio of 8.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VTVT in comparison with other companies in the Biotechnology industry. Currently, VTVT has a P/B value of 5.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VTVT
Add vTv Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VTVT